MedTrace Logo

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

NCT06405464 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-05-08

No results posted yet for this study

Summary

This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.

Conditions

  • HIV Infections

Interventions

DRUG

VOCABRIA 30Mg Tablet

CAB 30 mg Film-coated tablets

DRUG

EDURANT 25Mg Tablet

RPV 25 mg film-coated tablets

DRUG

Cabotegravir Injectable Suspension

CAB LA 600 mg prolonged release suspension for injection (3 mL)

DRUG

Rilpivirine Injectable Suspension

RPV LA 900 mg prolonged release suspension for injection (3 mL)

BIOLOGICAL

Intact proviral DNA assay

HIV-1 latent reservoir size

BIOLOGICAL

Full-length sequencing

Proviral DNA

Sponsors & Collaborators

  • Swiss HIV Cohort Study

    collaborator NETWORK

  • University of Zurich

    lead OTHER

Principal Investigators

  • Jessy J Duran Ramirez, MSc · Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405464 on ClinicalTrials.gov